Monopar Therapeutics' market value nearly tripled Thursday after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion.

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

AstraZeneca, a global biopharmaceutical company that develops and commercializes prescription medicines, became a household ...

Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is ...

AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the me | AstraZeneca has rolled out a ...

Monopar Therapeutics shares rose after the biotechnology company agreed to license a treatment for patients with a rare genetic condition from AstraZeneca unit Alexion. Shares of the Wilmette, Ill., ...

AstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...

Eccogene will receive a $60 million payment from AstraZeneca (AZN), which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for ...

AstraZeneca and Ionis are collaborating on the commercialisation of the drug following a December 2021 global agreement.

AstraZeneca’s new amenities centre, called The Hub, is up and running on Cambridge Biomedical Campus and hundreds of people ...